Voi siete qui

New drugs for the treatment of Cerebral Cavernous Malformation (CCM) pathology (n.210)

Field of use

Pharmaceuticals

inizio pagina


Description

The invention relates to a new use of known molecules for the systemic therapy of (Cerebral Cavernous Malformation) pathology, which is usually treated though observation and surgery. In particular the molecules herein proposed inhibit one of the pathways involved in the cerebral vascular lesions, thus preventing the onset of the disease. The molecule herein proposed, are already approved and used in oncology, in  musculoskeletal and immunogenic diseases, and are now proposed for CCM treatment, according to a repurposing strategy

inizio pagina


Advantages

The advantages of  the present invention relates to the fact the therapeutic intervention of CCM is exclusively surgical to date and there are not available drugs. The observation, that some known drugs, already approved in the clinic with different indications, can bind specific targets implicated in the onset of the disease, could be a great advantage in terms of approval and market approach.

inizio pagina


Suggested Applications

Systemic treatment of cerebral cavernous malformation (CCM).

inizio pagina


Inventors

Elisabetta Dejana
Maria Grazia Lampugnani

inizio pagina


Applicants

Università degli studi di Milano
IFOM

inizio pagina


Legal status

International Patent Application

inizio pagina


Contacts

For technical and scientific information:
Prof.ssa Elisabetta Dejana
Università degli Studi di Milano- Department of Biosciences
Elisabetta.dejana@unimi.it

inizio pagina